JP2016515141A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515141A5 JP2016515141A5 JP2016502876A JP2016502876A JP2016515141A5 JP 2016515141 A5 JP2016515141 A5 JP 2016515141A5 JP 2016502876 A JP2016502876 A JP 2016502876A JP 2016502876 A JP2016502876 A JP 2016502876A JP 2016515141 A5 JP2016515141 A5 JP 2016515141A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- biomarker
- treatment
- pharmaceutical composition
- absence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2013/072638 WO2014139131A1 (en) | 2013-03-14 | 2013-03-14 | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
| CNPCT/CN2013/072638 | 2013-03-14 | ||
| PCT/US2014/028714 WO2014153018A1 (en) | 2013-03-14 | 2014-03-14 | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019202804A Division JP2020040959A (ja) | 2013-03-14 | 2019-11-08 | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016515141A JP2016515141A (ja) | 2016-05-26 |
| JP2016515141A5 true JP2016515141A5 (enExample) | 2017-04-06 |
| JP6675300B2 JP6675300B2 (ja) | 2020-04-01 |
Family
ID=51535817
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502876A Expired - Fee Related JP6675300B2 (ja) | 2013-03-14 | 2014-03-14 | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 |
| JP2019202804A Pending JP2020040959A (ja) | 2013-03-14 | 2019-11-08 | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019202804A Pending JP2020040959A (ja) | 2013-03-14 | 2019-11-08 | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US10442862B2 (enExample) |
| JP (2) | JP6675300B2 (enExample) |
| WO (2) | WO2014139131A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014139131A1 (en) | 2013-03-14 | 2014-09-18 | Crown Bioscience, Inc. | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
| US10484156B2 (en) * | 2016-11-16 | 2019-11-19 | Qualcomm Incorporated | Search space associated with physical downlink control channel based on channel quality indicators |
| TWI859118B (zh) | 2017-03-29 | 2024-10-21 | 大陸商中美冠科生物技術（太倉）有限公司 | 測定對胃癌之西妥昔單抗（ｃｅｔｕｘｉｍａｂ）敏感性的系統及方法 |
| EP3635373B1 (en) * | 2017-06-06 | 2025-07-30 | University of Maryland, College Park | Analysis of single cell mechanical phenotyping for metastatic detection |
| CN107582993A (zh) * | 2017-11-10 | 2018-01-16 | 兰志英 | 一种治疗胃癌的药物及其制备方法 |
| WO2020100969A1 (ja) * | 2018-11-14 | 2020-05-22 | 学校法人金沢医科大学 | びまん性胃がんを治療するための医薬組成物 |
| CN115197320A (zh) * | 2021-04-07 | 2022-10-18 | 中美冠科生物技术（太仓）有限公司 | 新型抗cd4抗体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2527460B1 (en) | 2004-05-27 | 2014-12-24 | The Regents of The University of Colorado | Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients |
| WO2007076923A1 (en) | 2006-01-04 | 2007-07-12 | Merck Patent Gmbh | Combination therapy using anti-egfr and anti-her2 antibodies |
| US20090017050A1 (en) | 2007-07-13 | 2009-01-15 | Ventana Medical Systems, Inc. | Egfr antigen-binding molecules and uses thereof |
| US8583380B2 (en) * | 2008-09-05 | 2013-11-12 | Aueon, Inc. | Methods for stratifying and annotating cancer drug treatment options |
| EP2711704B1 (en) | 2011-05-16 | 2017-06-28 | Taiho Pharmaceutical Co., Ltd. | Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and egfr inhibitor |
| WO2014139131A1 (en) | 2013-03-14 | 2014-09-18 | Crown Bioscience, Inc. | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
-
2013
- 2013-03-14 WO PCT/CN2013/072638 patent/WO2014139131A1/en not_active Ceased
-
2014
- 2014-03-14 WO PCT/US2014/028714 patent/WO2014153018A1/en not_active Ceased
- 2014-03-14 JP JP2016502876A patent/JP6675300B2/ja not_active Expired - Fee Related
- 2014-03-14 US US14/775,117 patent/US10442862B2/en active Active
-
2019
- 2019-11-08 JP JP2019202804A patent/JP2020040959A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ajani et al. | Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology | |
| Pestana et al. | Histology-agnostic drug development—considering issues beyond the tissue | |
| De Jesus-Acosta et al. | Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma | |
| Ilson et al. | A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus | |
| Locati et al. | A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: translational analyses and clinical impact | |
| Prat et al. | Prediction of response to neoadjuvant chemotherapy using core needle biopsy samples with the prosigna assay | |
| Iveson et al. | Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study | |
| Fuchs et al. | Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab | |
| Ajani et al. | Esophageal and esophagogastric junction cancers, version 1.2015 | |
| Stintzing et al. | Prognostic value of cetuximab‐related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group | |
| Le et al. | Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas | |
| De Mattos-Arruda et al. | Translating neoadjuvant therapy into survival benefits: one size does not fit all | |
| Muller et al. | Expression of LRIG1 and LRIG3 correlates with human papillomavirus status and patient survival in cervical adenocarcinoma | |
| Wills et al. | Role of liquid biopsies in colorectal cancer | |
| González-Santiago et al. | Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study) | |
| Wang et al. | CC motif chemokine ligand 5 (CCL5) levels in gastric cancer patient sera predict occult peritoneal metastasis and a poorer prognosis | |
| Fleischmann et al. | ACO/ARO/AIO-21-Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group | |
| Jin et al. | Differential response to EGFR-and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases | |
| Pandey et al. | Personalized treatment approach for HER2-positive metastatic breast cancer | |
| Petrillo et al. | Biomarkers for precision treatment in gastric cancer | |
| Shuster et al. | Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer | |
| JP7298827B2 (ja) | 抗ｐｄ－１抗体若しくは抗ｐｄ－ｌ１抗体療法の奏効性を予測する方法、がんの悪性度を評価する方法、及び抗ｐｄ－１抗体若しくは抗ｐｄ－ｌ１抗体療法の奏効性を上昇させる方法 | |
| Akdogan et al. | The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer | |
| JP2019519772A (ja) | Ｈｅｒ２及びｈｅｒ３の経路サブタイピングに基づく乳癌患者の薬物療法の選択方法 | |
| Yonemori et al. | Contrasting prognostic implications of platelet-derived growth factor receptor-β and vascular endothelial growth factor receptor-2 in patients with angiosarcoma |